SEQSTER and CLEAR Forge Partnership
SEQSTER has launched a partnership with CLEAR to provide patients with Individual Access Services and allow them to securely access, control, and share their personal health information with authorized users. SEQSTER has integrated the CLEAR platform to allow patients to confirm their identity, access their medical records, and safely share them with various clinical trial research organizations within the SEQSTER Operating System for healthcare.
With this partnership, patients can now affirm their identity—with a government-issued ID and a selfie—to create and manage their SEQSTER account. Once a SEQSTER patient verifies their identity and creates their account, they can securely share their personal health information with SEQSTER’s life sciences partners.
Reference
SEQSTER and CLEAR Forge Partnership to Drive Innovation and Improve Patient Outcomes with Real-World Data. (2023, April 17). EIN Presswire.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
